mTOR inhibitors have been used in osteosarcomas, showing poor antineoplastic activity as monotherapy (67), probably due to the presence of many feedback loops in the IGF/PI3K/mTOR pathway. The gene discussed is PIK3CA; the disease is osteosarcoma.